Vuori Kristiina MD

Director Vuori Kristiina buys 6,667 shares of INBX at $15.00; holdings increase 48.4% in rapid succession of buys

Director Vuori Kristiina purchased 6,667 shares at $15.00 on 2024-10-03, increasing her holdings to 20,443 shares in a transaction worth $100,005.00. This purchase marks her third buy at Inhibrx in as many weeks (prior buys on 2024-09-11 and 2024-09-10), representing a 48.4% increase in holdings over the pre-transaction level of 13,776 shares. The transaction price of $15.00 sits at a significant discount to the 52-week high of $39.56, reflecting a -61.4% decline from peak levels. Notably, her most recent prior buy at this ticker on 2024-08-29 has delivered a +10.9% return over 30 days, consistent with her cross-ticker track record of +10.9% average 30-day returns on prior buys. The rapid accumulation pattern warrants attention to underlying business developments or valuation inflection points.

Director Kristiina Vuori bought 6,636 shares for $99,991.99 at Inhibrx in two transactions, raising holdings 92.9%.

Vuori made 2 separate purchases totaling 6,636 shares for $99,991.99, executed on consecutive trading days at prices of $15.00 and $15.07, increasing her stake from 7.1K shares to 13.8K shares. The current share price of $15.08 sits 61.9% below the 52-week high of $39.56, and the stock has recovered 33.4% over the past 30 days. Her cross-ticker track record shows only 1 prior buy with no measurable outcome history, and at Inhibrx specifically she executed an earlier buy on 2024-08-29 whose outcome remains unmeasured. The Company's fundamentals show quarterly revenue of $100,000.00 against net income of $1,858,011,000.00, indicating material losses, while the market cap stands at $218,296,632.32. This filing provides a data point on insider positioning but lacks sufficient historical pattern at this ticker to support timing inferences.

Director Vuori buys 7,140 INBX shares at $14.00; 3 other insiders also bought within 14 days in cluster pattern.

Director Kristiina MD Vuori purchased 7,140 shares at $14.00 on 2024-08-29, establishing an initial position in Inhibrx Biosciences. This buy occurs as part of a cluster pattern where 3 other insiders also purchased shares within the past 14 days, indicating coordinated insider interest at price levels well below the 52-week high of $39.56. The current price of $15.95 represents -59.7% from the 52-week high, placing this purchase in a depressed valuation window. The multi-insider activity within a compressed timeframe warrants analysis of whether this reflects material information unavailable to public markets or routine portfolio adjustments by board members.